Literature DB >> 2230877

Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33.

S Welt1, C R Divgi, F X Real, S D Yeh, P Garin-Chesa, C L Finstad, J Sakamoto, A Cohen, E R Sigurdson, N Kemeny.   

Abstract

A33 is a mouse immunoglobulin G2a (IgG2a) monoclonal antibody (mAb) that detects a heat-stable, protease- and neuraminidase-resistant epitope. The antigen is homogeneously expressed by virtually all colon cancers and in the colon mucosa but not other epithelial tissues. The biodistribution and imaging characteristics of iodine-131 (131I)-mAbA33 were studied in colorectal carcinoma patients with hepatic metastases. Antibody labeled with 2 to 5 mCi of 131I was administered intravenously (IV) 7 to 8 days before surgery at five dose levels, ranging from 0.2 mg to 50 mg, with three or more patients entered at each dose level. In addition, three patients received 2 mg 131I-mAbTA99 (an isotype-matched control mAb) together with 125I-mAbA33. Evaluation included whole-body imaging with a gamma camera, technetium-99 (99mTc)-human serum albumin blood pool scans, liver/spleen scans, abdominal computed tomographic (CT) scans, hepatic arteriograms, antibody pharmacokinetics, and assessment of antibody distribution in biopsied malignant and normal tissues. Selective mAbA33 localization to tumor tissue was demonstrated in 19 of 20 patients, and external imaging correlated with surgical inspection, pathologic examination, and tissue radioactivity. One week after antibody administration, tumor:liver ratios ranged from 6.9:1 to 100:1 and tumor:serum ratios from 4.1:1 to 25.2:1. 99mTc-albumin blood pool studies showed that liver metastases were hypovascular, emphasizing the selective localization of mAbA33 despite poor tumor-blood flow. Control mAbTA99 studies showed mAbA33 localization was antigen-specific; tumor:liver ratios were 2.3- to 45-fold higher for specific antibody. In metastatic lesions, radioisotope was localized primarily in the viable periphery; however, even the necrotic tumor core concentrated specific antibody. External imaging showed isotope visualization in some patients' large bowel; whether this represents specific antibody uptake or gastric iodine secretion is unclear.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2230877     DOI: 10.1200/JCO.1990.8.11.1894

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  29 in total

Review 1.  Clinical radioimmunotherapy--the role of radiobiology.

Authors:  Jean-Pierre Pouget; Isabelle Navarro-Teulon; Manuel Bardiès; Nicolas Chouin; Guillaume Cartron; André Pèlegrin; David Azria
Journal:  Nat Rev Clin Oncol       Date:  2011-11-08       Impact factor: 66.675

Review 2.  Monoclonal antibodies in cancer therapy.

Authors:  Andrew M Scott; James P Allison; Jedd D Wolchok
Journal:  Cancer Immun       Date:  2012-05-01

3.  A modular IgG-scFv bispecific antibody topology.

Authors:  Kelly Davis Orcutt; Margaret E Ackerman; Maryelise Cieslewicz; Emmanuel Quiroz; Adrian L Slusarczyk; John V Frangioni; K Dane Wittrup
Journal:  Protein Eng Des Sel       Date:  2009-12-17       Impact factor: 1.650

4.  The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily.

Authors:  J K Heath; S J White; C N Johnstone; B Catimel; R J Simpson; R L Moritz; G F Tu; H Ji; R H Whitehead; L C Groenen; A M Scott; G Ritter; L Cohen; S Welt; L J Old; E C Nice; A W Burgess
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

Review 5.  Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies.

Authors:  Egesta Lopci; Arturo Chiti; Maria Rita Castellani; Giovanna Pepe; Lidija Antunovic; Stefano Fanti; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

6.  (124)I-huA33 antibody PET of colorectal cancer.

Authors:  Jorge A Carrasquillo; Neeta Pandit-Taskar; Joseph A O'Donoghue; John L Humm; Pat Zanzonico; Peter M Smith-Jones; Chaitanya R Divgi; Daniel A Pryma; Shutian Ruan; Nancy E Kemeny; Yuman Fong; Douglas Wong; Jaspreet S Jaggi; David A Scheinberg; Mithat Gonen; Katherine S Panageas; Gerd Ritter; Achim A Jungbluth; Lloyd J Old; Steven M Larson
Journal:  J Nucl Med       Date:  2011-07-15       Impact factor: 10.057

7.  Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts.

Authors: 
Journal:  Int J Pancreatol       Date:  1994 Oct-Dec

8.  Clearance kinetics and external dosimetry of 131I-labeled murine and humanized monoclonal antibody A33 in patients with colon cancer: radiation safety implications.

Authors:  Lawrence T Dauer; Daniel C Boylan; Matthew J Williamson; Jean St Germain; Steven M Larson
Journal:  Health Phys       Date:  2009-05       Impact factor: 1.316

Review 9.  Technetium-99m methoxyisobutylisonitrile localizes an ectopic ACTH-producing tumour: case report and review of the literature.

Authors:  H Jacobsson; G Wallin; S Werner; S A Larsson
Journal:  Eur J Nucl Med       Date:  1994-06

10.  A33 antigen displays persistent surface expression.

Authors:  Margaret E Ackerman; Cecile Chalouni; Michael M Schmidt; Vivek V Raman; Gerd Ritter; Lloyd J Old; Ira Mellman; K Dane Wittrup
Journal:  Cancer Immunol Immunother       Date:  2008-07       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.